Dan Schell articles
-
How Takeda Leverages Cultural Competency Training To Improve Diversity
3/14/2024
Karen Correa, VP, head global clinical operations at Takeda, details some uncommon ways the pharma is tackling the problem of diversity in clinical trials.
-
Do ClinOps Professionals Understand The CAR-T Supply Chain?
3/4/2024
Lee Clough RN, HP, of Novartis talks about the importance of understanding the nuances associated with collecting and shipping autologous material (i.e., CAR-Ts) for clinical trials.
-
Ramblings From A First-Time SCOPE Attendee
2/15/2024
Dan Schell, chief editor of Clinical Leader, discusses what sessions stood out to him and some of the KOLs he rubbed elbows with while attending his first SCOPE Summit.
-
No Surprise: Patient Recruitment Still Sucks
2/14/2024
Patient recruitment expert Ross Jackson talks about why this part of the clinical trials ecosystem is still a problem and offers up some solutions, specifically around digital/social media outreach.
-
A Tribe Called SOS
2/5/2024
A first-hand account of a first-time industry conference. Dan Schell, chief editor of Clinical Leader, talks about his impressions of the Save Our Sites (SOS) conference that happened in Tucson, AZ on Feb. 2, 2024.
-
It's Hard To Predict AI's Real Value To Clinical Trials
2/1/2024
Sunny Kumar, a partner at GSR Ventures, plans to talk about AI and ML use in clinical trials during the SCOPE Summit panel, “The Future of Clinical Trial Tech: Perspectives from Different Investors.”
-
The Impact Of Protocol Design On An IRT System
1/31/2024
DTP and home treatment studies can get expensive — and be a hassle to patients — if the IRT element isn’t well planned for during trial design. In their SCOPE Summit presentation, Irina Grishina and Kelsey Kern of CSL Behring plan to share their personal anecdotes and lessons learned from both types of trials as they pertain to IRT.
-
What Is Clinical Trial Tokenization?
1/30/2024
Tokenization in clinical trials is still a new concept to many sponsors — and their patients who are volunteering for the studies. At his SCOPE Summit presentation, Tom Dougherty of Pfizer will explain this concept and discuss what trials are a fit.
-
A Closer Look At How RBQM Has Evolved In Recent Years
1/29/2024
Mary Arnould, senior director, program management/RBM lead, Clinical Science Operations at Astellas, talks about her SCOPE Summit 2024 presentation called “COVID-19 Pandemic Impact on Risk-Based Quality Management.”
-
Founders & Innovators To Share Clinical Trial Tech Insights
1/24/2024
Jodi Akin, founder of Hawthorne Effect, discusses some of the topics she will cover on the SCOPE Summit panel titled, “Overcoming Hurdles to Fundraising, Pilots, and Scaling” as part of the colocated Clinical Trial Tech: Venture, Innovation & Partnering event.